MaxCyte Investor Presentation Deck

Who We Are - Collaborative, Innovative and Experienced Partner Nasdaq Impact Scientific Foundation 1999 *As of December 31, 2022 24 SPL Partnerships Signed Since 2017 125 Employees* 30+ Field Sales and Application Scientists* Scalable GT Transfection System Cell Therapy 2000 FDA Master File 2002 Scalable STX Transfection System 2008 Listing London Stock Exchange/AIM LSE: MXCT, MXCN March 2016 London Stock Exchange ATX Gen 2 Transfection System Drug Discovery 2016 4 2018 m EXPERT™ Platform expert 2019 Listing Nasdaq MXCT July 2021 2021 M MaxCyte First MaxCyte- Enabled Approved Therapy Launch of EXPERT VLx/ Grand Opening Rockville, MD 2022 2023 © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation